O	0	11	Circulating
O	12	17	Tumor
O	18	21	DNA
O	22	29	Markers
O	30	33	for
O	34	39	Early
O	40	51	Progression
O	52	54	on
B-intervention	55	66	Fulvestrant
I-intervention	67	71	With
I-intervention	72	74	or
I-intervention	75	82	Without
I-intervention	83	94	Palbociclib
O	95	97	in
O	98	100	ER
O	100	101	+
O	102	110	Advanced
O	111	117	Breast
O	118	124	Cancer
O	124	125	.

O	126	131	There
O	132	135	are
O	136	138	no
O	139	150	established
O	151	160	molecular
O	161	171	biomarkers
O	172	175	for
O	176	184	patients
O	185	189	with
O	190	196	breast
O	197	203	cancer
O	204	213	receiving
O	214	225	combination
O	226	235	endocrine
O	236	239	and
O	240	244	CDK4
O	244	245	/
O	245	246	6
O	247	256	inhibitor
O	257	258	(
O	258	262	CDK4
O	262	263	/
O	263	265	6i
O	265	266	)
O	266	267	.

O	268	270	We
O	271	276	aimed
O	277	279	to
O	280	289	determine
O	290	297	whether
O	298	305	genomic
O	306	313	markers
O	314	316	in
O	317	328	circulating
O	329	334	tumor
O	335	338	DNA
O	339	340	(
O	340	345	ctDNA
O	345	346	)
O	347	350	can
O	351	359	identify
O	360	368	patients
O	369	371	at
O	372	378	higher
O	379	383	risk
O	384	386	of
O	387	392	early
O	393	404	progression
O	405	407	on
O	408	419	fulvestrant
O	420	427	therapy
O	428	432	with
O	433	435	or
O	436	443	without
O	444	455	palbociclib
O	455	456	,
O	457	458	a
O	459	463	CDK4
O	463	464	/
O	464	466	6i
O	466	467	.

O	468	474	PALOMA
O	474	475	-
O	475	476	3
O	477	480	was
O	481	482	a
O	483	488	phase
O	489	492	III
O	492	493	,
O	494	505	multicenter
O	505	506	,
O	507	513	double
O	513	514	-
O	514	519	blind
O	520	530	randomized
O	531	541	controlled
O	542	547	trial
O	548	550	of
O	551	562	palbociclib
O	563	567	plus
O	568	579	fulvestrant
O	580	581	(
O	581	582	n
O	583	584	=
B-intervention-participants	585	588	347
O	588	589	)
O	590	592	vs
B-control	593	600	placebo
I-control	601	605	plus
I-control	606	617	fulvestrant
O	618	619	(
O	619	620	n
O	621	622	=
B-control-participants	623	626	174
O	626	627	)
O	628	630	in
B-eligibility	631	639	patients
I-eligibility	640	644	with
I-eligibility	645	654	endocrine
I-eligibility	654	655	-
I-eligibility	655	665	pretreated
I-eligibility	666	674	estrogen
I-eligibility	675	683	receptor
I-eligibility	683	684	-
I-eligibility	684	692	positive
I-eligibility	693	694	(
I-eligibility	694	696	ER
I-eligibility	696	697	+
I-eligibility	697	698	)
I-eligibility	699	705	breast
I-eligibility	706	712	cancer
O	712	713	.

O	714	726	Pretreatment
O	727	733	plasma
O	734	741	samples
O	742	746	from
B-total-participants	747	750	459
O	751	759	patients
O	760	764	were
O	765	773	analyzed
O	774	777	for
O	778	787	mutations
O	788	790	in
O	791	793	17
O	794	799	genes
O	799	800	,
O	801	805	copy
O	806	812	number
O	813	815	in
O	816	818	14
O	819	824	genes
O	824	825	,
O	826	829	and
O	830	841	circulating
O	842	847	tumor
O	848	856	fraction
O	856	857	.

O	858	869	Progression
O	869	870	-
O	870	874	free
O	875	883	survival
O	884	885	(
O	885	888	PFS
O	888	889	)
O	890	893	was
O	894	902	compared
O	903	905	in
O	906	914	patients
O	915	919	with
O	920	931	circulating
O	932	937	tumor
O	938	946	fraction
O	947	952	above
O	953	955	or
O	956	961	below
O	962	963	a
O	964	976	prespecified
O	977	983	cutoff
O	984	986	of
O	987	989	10
O	989	990	%
O	991	994	and
O	995	999	with
O	1000	1002	or
O	1003	1010	without
O	1011	1012	a
O	1013	1021	specific
O	1022	1029	genomic
O	1030	1040	alteration
O	1040	1041	.

O	1042	1045	All
O	1046	1057	statistical
O	1058	1063	tests
O	1064	1068	were
O	1069	1070	2
O	1070	1071	-
O	1071	1076	sided
O	1076	1077	.

O	1078	1086	Patients
O	1087	1091	with
O	1092	1096	high
O	1097	1102	ctDNA
O	1103	1111	fraction
O	1112	1115	had
O	1116	1121	worse
B-outcome	1122	1125	PFS
O	1126	1128	on
O	1129	1133	both
O	1134	1145	palbociclib
O	1146	1150	plus
O	1151	1162	fulvestrant
O	1163	1164	(
O	1164	1170	hazard
O	1171	1176	ratio
O	1177	1178	[
O	1178	1180	HR
O	1180	1181	]
O	1182	1183	=
O	1184	1185	1
O	1185	1186	.
O	1186	1188	62
O	1188	1189	,
O	1190	1192	95
O	1192	1193	%
O	1194	1204	confidence
O	1205	1213	interval
O	1214	1215	[
O	1215	1217	CI
O	1217	1218	]
O	1219	1220	=
O	1221	1222	1
O	1222	1223	.
O	1223	1225	17
O	1226	1228	to
O	1229	1230	2
O	1230	1231	.
O	1231	1233	24
O	1233	1234	;
O	1235	1236	P
O	1237	1238	=
O	1239	1240	.
O	1240	1243	004
O	1243	1244	)
O	1245	1248	and
O	1249	1256	placebo
O	1257	1261	plus
O	1262	1273	fulvestrant
O	1274	1275	(
O	1275	1277	HR
O	1278	1279	=
O	1280	1281	1
O	1281	1282	.
O	1282	1284	77
O	1284	1285	,
O	1286	1288	95
O	1288	1289	%
O	1290	1292	CI
O	1293	1294	=
O	1295	1296	1
O	1296	1297	.
O	1297	1299	21
O	1300	1302	to
O	1303	1304	2
O	1304	1305	.
O	1305	1307	59
O	1307	1308	;
O	1309	1310	P
O	1311	1312	=
O	1313	1314	.
O	1314	1317	004
O	1317	1318	)
O	1318	1319	.

O	1320	1322	In
O	1323	1336	multivariable
O	1337	1345	analysis
O	1345	1346	,
O	1347	1351	high
O	1351	1352	-
O	1352	1363	circulating
O	1364	1369	tumor
O	1370	1378	fraction
O	1379	1382	was
O	1383	1393	associated
O	1394	1398	with
O	1399	1404	worse
B-outcome	1405	1408	PFS
O	1409	1410	(
O	1410	1412	HR
O	1413	1414	=
O	1415	1416	1
O	1416	1417	.
O	1417	1419	20
O	1420	1423	per
O	1424	1426	10
O	1426	1427	%
O	1428	1436	increase
O	1437	1439	in
O	1440	1445	tumor
O	1446	1454	fraction
O	1454	1455	,
O	1456	1458	95
O	1458	1459	%
O	1460	1462	CI
O	1463	1464	=
O	1465	1466	1
O	1466	1467	.
O	1467	1469	09
O	1470	1472	to
O	1473	1474	1
O	1474	1475	.
O	1475	1477	32
O	1477	1478	;
O	1479	1480	P
O	1481	1482	<
O	1483	1484	.
O	1484	1487	001
O	1487	1488	)
O	1488	1489	,
O	1490	1492	as
O	1493	1496	was
B-outcome	1497	1501	TP53
I-outcome	1502	1510	mutation
O	1511	1512	(
O	1512	1514	HR
O	1515	1516	=
O	1517	1518	1
O	1518	1519	.
O	1519	1521	84
O	1521	1522	,
O	1523	1525	95
O	1525	1526	%
O	1527	1529	CI
O	1530	1531	=
O	1532	1533	1
O	1533	1534	.
O	1534	1536	27
O	1537	1539	to
O	1540	1541	2
O	1541	1542	.
O	1542	1544	65
O	1544	1545	;
O	1546	1547	P
O	1548	1549	=
O	1550	1551	.
O	1551	1554	001
O	1554	1555	)
O	1556	1559	and
B-outcome	1560	1565	FGFR1
I-outcome	1566	1579	amplification
O	1580	1581	(
O	1581	1583	HR
O	1584	1585	=
O	1586	1587	2
O	1587	1588	.
O	1588	1590	91
O	1590	1591	,
O	1592	1594	95
O	1594	1595	%
O	1596	1598	CI
O	1599	1600	=
O	1601	1602	1
O	1602	1603	.
O	1603	1605	61
O	1606	1608	to
O	1609	1610	5
O	1610	1611	.
O	1611	1613	25
O	1613	1614	;
O	1615	1616	P
O	1617	1618	<
O	1619	1620	.
O	1620	1623	001
O	1623	1624	)
O	1624	1625	.

O	1626	1628	No
O	1629	1640	interaction
O	1641	1645	with
O	1646	1655	treatment
O	1656	1669	randomization
O	1670	1673	was
O	1674	1682	observed
O	1682	1683	.

O	1684	1696	Pretreatment
O	1697	1702	ctDNA
O	1703	1713	identified
O	1714	1715	a
O	1716	1721	group
O	1722	1724	of
O	1725	1729	high
O	1729	1730	-
O	1730	1734	risk
O	1735	1743	patients
O	1744	1748	with
O	1749	1753	poor
O	1754	1762	clinical
O	1763	1770	outcome
O	1771	1778	despite
O	1779	1782	the
O	1783	1791	addition
O	1792	1794	of
O	1795	1799	CDK4
O	1799	1800	/
O	1800	1801	6
O	1802	1812	inhibition
O	1812	1813	.

O	1814	1819	These
O	1820	1828	patients
O	1829	1834	might
O	1835	1842	benefit
O	1843	1847	from
O	1848	1857	inclusion
O	1858	1860	in
O	1861	1867	future
O	1868	1874	trials
O	1875	1877	of
O	1878	1888	escalating
O	1889	1898	treatment
O	1898	1899	,
O	1900	1904	with
O	1905	1914	therapies
O	1915	1919	that
O	1920	1923	may
O	1924	1926	be
O	1927	1933	active
O	1934	1936	in
O	1937	1942	these
O	1943	1950	genomic
O	1951	1959	contexts
O	1959	1960	.
